Product Name | Imatinib mesylate |
Description |
Kinase inhibitor |
Purity | >98% (HPLC) |
CAS No. | 152459-95-5 |
Molecular Formula | C30H35N7O4S |
Molecular Weight | 589.7 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble H2O: soluble10 mg/ml, clear |
Source | Synthetic |
Appearance | White to beige solid |
SMILES | C5=C(C1=CN=CC=C1)N=C(NC2=C(C=CC(=C2)NC(C3=CC=C(C=C3)CN4CCN(CC4)C)=O)C)N=C5 |
InChI | InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) |
InChIKey | KTUFNOKKBVMGRW-UHFFFAOYSA-N |
Safety Phrases |
Classification: Acute toxicity, Oral (Category 4), H302 Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H302 Harmful if swallowed. Precautionary statements: P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. P330 Rinse mouth. P501 Dispose of contents/ container to an approved waste disposal plant. |
Cite This Product | Imatinib mesylate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-453) |
Alternative Names | 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate, 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate, CGP 57148, Genfatinib, Glivec, Imatinib methanesulfonate, STI-571 |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 5291 |
Scientific Background | Imatinib mesylate is a tyrosine kinase inhibitor. It specifically inhibits Bcr-Abl tyrosine kinase, and receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. |
References | 1. Kantarjian H., et al. (2002). N.E. J. Med. 346(9): 645–652. |
Reviews
There are no reviews yet.